|
|
Can You Diagnose this Patient with Edema, Pain, Abdominal Swelling, and/or Fatigue?
When your patient presents with symptoms such as edema, fatigue, and abdominal pain, what might you first suspect and can you reach the right diagnosis? Put your diagnostic skills to the test! In just 15 minutes, navigate through real-world cases and upon completion, hear faculty insights on the implications of your decisions along with rationales for appropriate next steps to aid in making a final diagnosis, as well as evidence-based treatment strategies. Apply the latest scientific evidence ... |
|
|
Mastering Treatment-Naive DME
In this Master Class case, Dr. Mark R. Barakat discusses the management of a 76-year-old White man with treatment-naive diabetic macular edema. |
|
|
Mastering Suboptimal Treatment Response in DME
In this Master Class case, Dr. W. Lloyd Clark discusses the management of a 75-year-old Black woman with diabetic macular edema who has a suboptimal treatment response to initial anti-vascular epithelial growth factor therapy. |
|
|
Mastering Treatment-Refractory DME
In this Master Class case, Dr. Diana Do discusses the management of a 58-year-old White woman with treatment-refractory diabetic macular edema. |
|
|
Bridging the Health Gaps in Hereditary Angioedema: Demystifying Disparities, Enhancing Quality of Life, and Implementing Effective Prophylactic Solutions
Hereditary angioedema (HAE) is a rare, life-threatening disorder characterized by recurrent, unpredictable episodes of bradykinin-induced swelling. In this presentation, Dr. Marc Reidl, Clinical Director of the US Hereditary Angioedema Association (HAEA) Angioedema Center, reviews multiple underrecognized factors that contribute to health disparities among patients with HAE, including delays in diagnosis and multifaceted differences among racial and ethnic groups, socioeconomic status levels, ... |
|
|
nAMD and DME: Novel Treatment Plans to Prioritize Real-World Visual Improvements
Frequent intravitreal injections of anti-vascular endothelial growth factor (VEGF) therapies can significantly improve visual and anatomical outcomes for many patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, the requisite high number of treatments often leads to less-than-ideal results compared to outcomes reported in major clinical trials, largely due to the demanding treatment schedule. Adopting tailored treatment plans, along with ... |
|
|
Extending Dosing Intervals in Retinal Disease: Patient Perspectives and Clinical Insights to Guide Your Practice
Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are increasingly prevalent retinal diseases that pose significant challenges in ophthalmic care. While anti-vascular endothelial growth factor (VEGF) therapies have greatly improved visual outcomes for patients with these conditions, real-world data indicate that many patients receive suboptimal treatment and monitoring, resulting in poorer visual outcomes. Newer therapeutic options have been developed to exte... |
|
|
The Retina Radar With Dr. Arshad Khanani on DR, GA, New Mechanisms, and Noninvasive Treatments
Retinal diseases are a leading cause of global vision impairment, driven by an increasing prevalence and the need for more effective treatment. Although clinical trials have shown promising results for various therapies, real-world application often yields less impressive outcomes due to factors like under-treatment and patient non-adherence. New and emerging therapies, particularly for conditions like diabetic macular edema (DME), diabetic retinopathy, and geographic atrophy (GA) secondary to... |
|